Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.
NCT02224560 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 8, 2015
- Completion date
- May 19, 2016
- Enrollment
- 225 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.